Oncoceutics Commemorates Brain Tumor Awareness Month

Philadelphia, PA (May 5, 2020) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates Brain Tumor Awareness Month this May and expresses its support for all those affected by brain tumors. Brain tumors remain one of the greatest current health challenges as there are limited treatment options for patients, and prognoses continue to be poor.
 
“In commemorating this month, we recognize not only the patients currently battling brain cancer, but also the families of those patients, the clinicians and caregivers treating them, the survivors, the patients who have lost their lives, and the researchers working to defeat this disease,” said Lee Schalop, MD, Chief Executive Officer of Oncoceutics. “Over the last decades, little progress to secure new and effective treatments has been made in the battle against brain cancer, and there remains a strong need for new and innovative approaches to help change the future of this terrible disease.”
 
“Oncoceutics remains committed to changing the treatment landscape and drug development approach for brain cancer, and we are honored to be working with leading cancer centers, researchers, and patient advocacy groups,” added Joshua Allen, PhD, Chief Scientific Officer of Oncoceutics. “We recognize the importance of Brain Tumor Awareness Month in bringing national attention to this devastating disease, and encourage the public to support patient advocacy groups, learn more about the latest treatment options, and join us in commemorating this month.”
 
Emerging clinical trial results with ONC201, the company’s lead development candidate, with a subtype of brain cancer called H3 K27M-mutant glioma, are encouraging. This specific mutation occurs at a particularly high rate among children and young adults who have gliomas located in the midline structures of the brain where surgery is difficult and treatments for other forms of brain cancer are not effective. Ongoing clinical trials to evaluate ONC201 for patients with H3 K27M-mutant gliomas can be found on clinicaltrials.gov: NCT03416530, NCT03295396, NCT03295396.
 
To learn more about Brain Tumor Awareness Month and how to get involved, visit:
https://www.cancer.gov/rare-brain-spine-tumor/blog/2019/brain-tumor-awareness
 
About Oncoceutics
 
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds called imipridones that selectively target G protein-coupled receptors for oncology. The first lead compound to emerge from this program is ONC201, an orally active small molecule DRD2 antagonist and ClpP agonist. The company is supported by grants from NCI, FDA, The Musella Foundation, and the National Brain Tumor Society, and a series of private and public partnerships. Visit Oncoceutics.com for more information.